Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors

Abstract

It is well established that alterations in phosphate metabolism have a profound effect on hard and soft tissues of the oral cavity. The present-day clinical form of osteonecrosis of the jaw (ONJ) was preceded by phosphorus necrosis of the jaw, ca. 1860. The subsequent removal of yellow phosphorus from matches in the early 20th century saw a parallel decline in “phossy jaw” until the early 2000s, when similar reports of unusual jaw bone necrosis began to appear in the literature describing jaw necrosis in patients undergoing chemotherapy and concomitant steroid and bisphosphonate treatment. Today, the potential side effect of ONJ associated with medications that block osteoclast activity (antiresorptive) is well known, though the mechanism remains unclear and the management and outcomes are often unsatisfactory. Much of the existing literature has focused on the continuing concerns of appropriate use of bisphosphonates and other antiresorptive medications, the incomplete or underdeveloped research on ONJ, and the use of drugs with anabolic potential for treatment of osteoporosis. While recognizing that ONJ is a rare occurrence and ONJ-associated medications play an important role in fracture risk reduction in osteoporotic patients, evidence to date suggests that health care providers can lower the risk further by dental evaluations and care prior to initiating antiresorptive therapies and by monitoring dental health during and after treatment. This review describes the current clinical management guidelines for ONJ, the critical role of dental-medical management in mitigating risks, and the current understanding of the effects of predominantly osteoclast-modulating drugs on bone homeostasis.

References

[1] Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J. Oral. Maxillofac. Surg., 2003, 61:1104-1107

[2] Ruggiero SL et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J. Oral. Maxillofac. Surg., 2014, 72:1938-1956

[3] Drugs for postmenopausal osteoporosis. JAMA 321, 2233–2234 (2019).

[4] Holtmann H et al. Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials. J. Int. Med. Res., 2018, 46:4277-4296

[5] Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharm. Exp. Ther., 2005, 315:971-979

[6] Fournier P et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res., 2002, 62:6538-6544

[7] Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Investig., 2004, 114:623-633

[8] Wood J et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharm. Exp. Ther., 2002, 302:1055-1061

[9] Fournier P et al. The bisphosphonate rise-dronate inhibits both angiogenesis and bone metastasis formation in vivo. Proc. Am. Assoc. Cancer Res., 2003, 44:1256-1257

[10] Zhou DY et al. Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models. Oncol. Lett., 2017, 14:4078-4084

[11] Jonasson G, Skoglund I, Rythen M. The rise and fall of the alveolar process: dependency of teeth and metabolic aspects. Arch. Oral. Biol., 2018, 96:195-200

[12] Ruggiero SL, Mehrotra B. Ten years of alendronate treatment for osteoporosis in postmenopausal women. N. Engl. J. Med., 2004, 351:190-192

[13] Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral. Maxillofac. Surg., 2004, 62:527-534

[14] Edwards BJ et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol., 2008, 9:1166-1172

[15] Di Fede O et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. BioMed. Res. Int., 2018, 2018:2684924

[16] de Molon RS et al. Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model. Bone, 2014, 68:11-19

[17] Marx RE. Uncovering the cause of “phossy jaw” Circa 1858 to 1906: oral and maxillofacial surgery closed case files-case closed. J. Oral. Maxillofac. Surg., 2008, 66:2356-2363

[18] Marx RE. Clinical concerns of alendronate use. J. Oral. Maxillofac. Surg., 2008, 66:1322

[19] Chang J, Hakam AE, McCauley LK. Current understanding of the pathophysiology of osteonecrosis of the jaw. Curr. Osteoporos. Rep., 2018, 16:584-595

[20] Sturrock A, Preshaw PM, Hayes C, Wilkes S. General dental practitioners’ perceptions of, and attitudes towards, improving patient safety through a multidisciplinary approach to the prevention of medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in the North East of England. BMJ Open, 2019, 9

[21] Khosla S et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Min. Res., 2007, 22:1479-1491

[22] Schiodt M, Reibel J, Oturai P, Kofod T. Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radiol., 2014, 117:204-213

[23] Colella G, Campisi G, Fusco V. American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate-related osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition. J. Oral. Maxillofac. Surg., 2009, 67:2698-2699

[24] Ruggiero SL et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws–2009 update. J. Oral. Maxillofac. Surg., 2009, 67:2-12

[25] Oteri G et al. Treatment of medication-related osteonecrosis of the jaw and its impact on a patient’s quality of life: a single-center, 10-year experience from southern Italy. Drug Saf., 2018, 41:111-123

[26] Yarom N et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos. Int., 2007, 18:1363-1370

[27] Taguchi A, Shiraki M, Sugimoto T, Ohta H, Soen S. Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw. Curr. Med. Res. Opin., 2016, 32:1261-1268

[28] Dimopoulos MA et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. Off. J. Eur. Soc. Med. Oncol., 2009, 20:117-120

[29] Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J. Can. Dent. Assoc., 2011, 77:b147

[30] Vandone AM et al. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 2012, 23:193-200

[31] Kim KM et al. Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J. Bone Metab., 2015, 22:151-165

[32] Khan AA et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Min. Res., 2015, 30:3-23

[33] American Association of Endodontists. Endodontic Implications of Medication-Related Osteonecrosis of the Jaw [online]. American Association of Endodontists Position Paper. Available at: https://www.aae.org/specialty/wp-content/uploads/sites/2/2018/07/AAE_MedRelated_ONJ.pdf (2018).

[34] Svejda, B. et al. Position paper on medication-related osteonecrosis of the jaw (MRONJ). Wien Med Wochenschr. 166, 68–74 (2016).

[35] Hellstein JW et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J. Am. Dent. Assoc., 2011, 142:1243-1251

[36] Barasch A et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J. Dent. Res., 2011, 90:439-444

[37] Barasch A et al. Dental risk factors for osteonecrosis of the jaws: a CONDOR case-control study. Clin. Oral. Investig., 2013, 17:1839-1845

[38] Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst. Rev., 2017, 10:CD012432

[39] Adler RA et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J. Bone Min. Res., 2016, 31:16-35

[40] Jung SY, Suh HS, Park JW, Kwon JW. Drug holiday patterns and bisphosphonate-related osteonecrosis of the jaw. Oral. Dis., 2019, 25:471-480

[41] Eastell R et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* Clinical Practice Guideline. J. Clin. Endocrinol. Metab., 2019, 104:1595-1622

[42] Siu, A., Allore, H., Brown, D., Charles, S. T. & Lohman, M. National Institutes of Health Pathways to Prevention Workshop: research gaps for long-term drug therapies for osteoporotic fracture prevention. Ann. Intern. Med. 171, 51–57 (2019).

[43] Bilezikian JP. Osteonecrosis of the jaw–do bisphosphonates pose a risk? N. Engl. J. Med., 2006, 355:2278-2281

[44] Thumbigere-Math V et al. Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. J. Periodontol., 2014, 85:226-233

[45] Williams DW et al. Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-kappaB ligand antibody in mice. Am. J. Pathol., 2014, 184:3084-3093

[46] Vahtsevanos K et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J. Clin. Oncol., 2009, 27:5356-5362

[47] Kyrgidis A et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J. Clin. Oncol., 2008, 26:4634-4638

[48] Watts NB et al. Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years. J. Clin. Endocrinol. Metab., 2019, 104:2443-2452

[49] O’Ryan FS et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J. Oral. Maxillofac. Surg., 2009, 67:1363-1372

[50] Fedele S et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am. J. Med, 2010, 123:1060-1064

[51] Guarneri V et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res. Treat., 2010, 122:181-188

[52] Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J. Oral. Maxillofac. Surg., 2013, 71:1532-1540

[53] Ayllon J et al. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 2009, 20:600-601

[54] Christodoulou C et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology, 2009, 76:209-211

[55] Saad F et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 2012, 23:1341-1347

[56] Viviano M, Rossi M, Cocca S. A rare case of osteonecrosis of the jaw related to imatinib. J. Korean Assoc. Oral. Maxillofac. Surg., 2017, 43:120-124

[57] Pimolbutr K, Porter S, Fedele S. Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-naive patient: a comprehensive review of the literature. BioMed. Res. Int., 2018, 2018:8071579

[58] Antonuzzo L et al. Osteonecrosis of the jaw and angiogenesis inhibitors: a revival of a rare but serous side effect. Curr. Med. Chem., 2017, 24:3068-3076

[59] Fleisher KE et al. Comorbid conditions are a risk for osteonecrosis of the jaw unrelated to antiresorptive therapy. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio., 2019, 127:140-150

[60] Lo JC et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J. Oral. Maxillofac. Surg., 2010, 68:243-253

[61] Malden N, Lopes V. An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. J. Bone Miner. Metab., 2012, 30:171-182

[62] Henry DH et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol., 2011, 29:1125-1132

[63] Lo J, Xia JJ, Zwahlen RA, Cheung LK. Surgical navigation in correction of hemimandibular hyperplasia: a new treatment strategy. J. Oral. Maxillofac. Surg., 2010, 68:1444-1450

[64] Waples, Y. Summary minutes of the joint meeting of the advisory committee for reproductive health drugs and drug safety and risk management advisory committee September 9, 2011. https://wayback.archive-it.org/7993/20170404150117/https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM278481.pdf (2011).

[65] Messer JG et al. Zoledronate treatment duration is linked to bisphosphonate-related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis. Oral. Dis., 2019, 25:1116-1135

[66] Hall BE et al. Conditional overexpression of TGF-beta1 disrupts mouse salivary gland development and function. Lab. Investig. J. Tech. Methods Pathol., 2010, 90:543-555

[67] Wu AJ et al. Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by interferon-gamma in a human salivary gland cell line. J. Cell. Physiol., 1997, 171:117-124

[68] Hulkkonen J et al. Matrix metalloproteinase 9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren’s syndrome. Rheumatology, 2004, 43:1476-1479

[69] Liao MT et al. Increased risk of bisphosphonate-related osteonecrosis of the jaw in patients with Sjogren’s syndrome: nationwide population-based cohort study. BMJ Open, 2019, 9

[70] Hennedige AA, Jayasinghe J, Khajeh J, Macfarlane TV. Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta. J. Oral. Maxillofac. Res., 2013, 4

[71] Nasomyont N, Hornung LN, Gordon CM, Wasserman H. Outcomes following intravenous bisphosphonate infusion in pediatric patients: a 7-year retrospective chart review. Bone, 2019, 121:60-67

[72] Andronowski JM, Crowder C, Soto Martinez M. Recent advancements in the analysis of bone microstructure: new dimensions in forensic anthropology. Forensic Sci. Res., 2018, 3:278-293

[73] Unal M, Creecy A, Nyman JS. The role of matrix composition in the mechanical behavior of bone. Curr. Osteoporos. Rep., 2018, 16:205-215

[74] Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin. Ther., 2007, 29:1548-1558

[75] Oliveira CC, Brizeno LA, de Sousa FB, Mota MR, Alves AP. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab)—review. Med. Oral Patol. Oral Cir. Bucal, 2016, 21:e431-e439

[76] Inada A et al. Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database. Ther. Clin. Risk Manag., 2019, 15:59-64

[77] Grbic JT et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J. Am. Dent. Assoc., 2008, 139:32-40

[78] Kuroshima S, Sasaki M, Sawase T. Medication-related osteonecrosis of the jaw: a literature review. J. Oral. Biosci, 2019, 61:99-104

[79] Foster BL et al. Rare bone diseases and their dental, oral, and craniofacial manifestations. J. Dent. Res., 2014, 93:7S-19S

[80] Marini F et al. Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Front. Biosci. (Elite Ed.), 2011, 3:364-370

[81] Sarasquete ME et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood, 2008, 112:2709-2712

[82] English BC et al. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther. Clin. Risk Manag., 2010, 6:579-583

[83] Yang G et al. SIRT1/HERC4 locus associated with bisphosphonate-induced osteonecrosis of the jaw: an exome-wide association analysis. J. Bone Min. Res., 2018, 33:91-98

[84] Subramaniyan B, Jagadeesan K, Ramakrishnan S, Mathan G. Targeting the interaction of Aurora kinases and SIRT1 mediated by Wnt signaling pathway in colorectal cancer: a critical review. Biomed. Pharmacother., 2016, 82:413-424

[85] Severe N, Dieudonne FX, Marie PJ. E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis. Cell Death Dis., 2013, 4

[86] Yang R, Tao Y, Wang C, Shuai Y, Jin L. Circulating microRNA panel as a novel biomarker to diagnose bisphosphonate-related osteonecrosis of the jaw. Int. J. Med. Sci., 2018, 15:1694-1701

[87] Lorenzo-Pouso AI et al. Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: a systematic review. Med. Oral. Patol. Oral. Cir. Bucal, 2019, 24:e26-e36

[88] Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J. Dent. Res., 2007, 86:1022-1033

[89] Li B, Ling Chau JF, Wang X, Leong WF. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy. J. Cell. Biochem., 2011, 112:1229-1242

[90] Wen D, Qing L, Harrison G, Golub E, Akintoye SO. Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate. Oral Dis., 2011, 17:427-432

[91] Gong X, Yu W, Zhao H, Su J, Sheng Q. Skeletal site-specific effects of zoledronate on in vivo bone remodeling and in vitro BMSCs osteogenic activity. Sci. Rep., 2017, 7

[92] Lungu AE et al. Observational study of the bisphosphonate-related osteonecrosis of jaws. Clujul Med. (1957), 2018, 91:209-215

[93] Vardimon AD, Beckmann S, Shpack N, Sarne O, Brosh T. Posterior and anterior components of force during bite loading. J. Biomech., 2007, 40:820-827

[94] Rues S, Lenz J, Turp JC, Schweizerhof K, Schindler HJ. Muscle and joint forces under variable equilibrium states of the mandible. Clin. Oral Investig., 2011, 15:737-747

[95] Zhao Y et al. The remodeling of alveolar bone supporting the mandibular first molar with different levels of periodontal attachment. Med. Biol. Eng. Comput., 2013, 51:991-997

[96] Hokugo A, Sun S, Park S, McKenna CE, Nishimura I. Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats. Bone, 2013, 53:59-68

[97] Gertz BJ et al. Studies of the oral bioavailability of alendronate. Clin. Pharmacol. Ther., 1995, 58:288-298

[98] Fleisher KE et al. Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. J. Oral. Maxillofac. Surg., 2013, 71:513-519

[99] Bataille C et al. Different sympathetic pathways control the metabolism of distinct bone envelopes. Bone, 2012, 50:1162-1172

[100] Mah W et al. Gain-of-function mutation in TRPV4 identified in patients with osteonecrosis of the femoral head. J. Med. Genet., 2016, 53:705-709

[101] Kato Y et al. Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and inflammatory pain. Proc. Natl Acad. Sci. USA., 2017, 114:E6297-E6305

[102] Hojo K, Tamai R, Kobayashi-Sakamoto M, Kiyoura Y. Etidronate down-regulates toll-like receptor (TLR) 2 ligand-induced proinflammatory cytokine production by inhibiting NF-kappaB activation. Pharm. Rep., 2017, 69:773-778

[103] Florenzano P et al. Age-related changes and effects of bisphosphonates on bone turnover and disease progression in fibrous dysplasia of bone. J. Bone Min. Res, 2019, 34:653-660

[104] Wang Y et al. Efficacy and safety of bisphosphonate therapy in mccune-albright syndrome-related polyostotic fibrous dysplasia: a single-center experience. Endocr. Pract., 2019, 25:23-30

[105] Walter C, Pabst A, Ziebart T, Klein M, Al-Nawas B. Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis., 2011, 17:194-199

[106] Ziebart T et al. Investigation of inhibitory effects on EPC-mediated neovascularization by different bisphosphonates for cancer therapy. Biomed. Rep., 2013, 1:719-722

[107] Wehrhan F et al. Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue. Oral. Surg. Oral. Med Oral. Pathol. Oral. Radio. Endod., 2011, 112:216-221

[108] Tanoue R, Koi K, Yamashita J. Effect of alendronate on bone formation during tooth extraction wound healing. J. Dent. Res., 2015, 94:1251-1258

[109] Tseng HC et al. Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation. Oncotarget, 2015, 6:20002-20025

[110] Kuroshima S, Al-Salihi Z, Yamashita J. Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow. Clin. Oral Investig., 2016, 20:727-736

[111] Yamashita J, McCauley LK, Van Poznak C. Updates on osteonecrosis of the jaw. Curr. Opin. Support. Palliat. Care, 2010, 4:200-206

[112] Haber SL, McNatty D. An evaluation of the use of oral bisphosphonates and risk of esophageal cancer. Ann. Pharmacother., 2012, 46:419-423

[113] Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol. Pharm., 2001, 59:193-202

[114] Lee RS et al. Bisphosphonate inhibits the expression of cyclin A2 at the transcriptional level in normal human oral keratinocytes. Int. J. Mol. Med., 2017, 40:623-630

[115] Bae S et al. Development of oral osteomucosal tissue constructs in vitro and localization of fluorescently-labeled bisphosphonates to hard and soft tissue. Int. J. Mol. Med., 2014, 34:559-563

[116] Zhu W et al. Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw. FASEB J., 2019, 33:5208-5219

[117] Tseng, H. C. et al. Erratum: bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation. Oncotarget 6, 41398 (2015).

[118] Bagan J et al. Interleukin-6 concentration changes in plasma and saliva in bisphosphonate-related osteonecrosis of the jaws. Oral Dis., 2014, 20:446-452

[119] Park S et al. Osteonecrosis of the jaw developed in mice: disease variants regulated by gammadelta T cells in oral mucosal barrier immunity. J. Biol. Chem., 2015, 290:17349-17366

[120] Sun Y et al. Plasticity of myeloid cells during oral barrier wound healing and the development of bisphosphonate-related osteonecrosis of the jaw. J. Biol. Chem., 2016, 291:20602-20616

[121] Messer JG et al. Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis. Bone, 2018, 108:79-88

[122] Boff RC, Salum FG, Figueiredo MA, Cherubini K. Important aspects regarding the role of microorganisms in bisphosphonate-related osteonecrosis of the jaws. Arch. Oral Biol., 2014, 59:790-799

[123] Pushalkar S et al. Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the jaw. Int J. Oral Sci., 2014, 6:219-226

[124] Hadaya D et al. Nonsurgical management of medication-related osteonecrosis of the jaws using local wound care. J. Oral Maxillofac. Surg., 2018, 76:2332-2339

[125] Ermer MA et al. In vitro investigation of the antimicrobial effect of three bisphosphonates against different bacterial strains. J. Oral Maxillofac. Surg., 2018, 76:553-560

[126] Petrukhina NB, Zorina OA, Shikh EV, Shibaeva AV, Shevelev AB. Study of mutual dependence of periodontal and colonic microbiome in health and pathology using NSG-sequencing. Stomatologiia, 2016, 95:8-13

[127] Hathaway-Schrader JD et al. Antibiotic perturbation of gut microbiota dysregulates osteoimmune cross talk in postpubertal skeletal development. Am. J. Pathol., 2019, 189:370-390

[128] Khan AA et al. Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J. Clin. Densitom., 2017, 20:8-24

[129] Chapple IL, Matthews JB. The role of reactive oxygen and antioxidant species in periodontal tissue destruction. Periodontol 2000, 2007, 43:160-232

[130] Kim S et al. IL-36 induces bisphosphonate-related osteonecrosis of the jaw-like lesions in mice by inhibiting TGF-beta-mediated collagen expression. J. Bone Min. Res., 2017, 32:309-318

[131] Gong L, Altman RB, Klein TE. Bisphosphonates pathway. Pharmacogenet. Genom., 2011, 21:50-53.

[132] Shoji K, Horiuchi H, Shinoda H. Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats. J. Periodontal. Res., 1995, 30:277-284

[133] Jeong SY et al. Combined effect of recombinant human bone morphogenetic protein-2 and low level laser irradiation on bisphosphonate-treated osteoblasts. J. Korean Assoc. Oral. Maxillofac. Surg., 2018, 44:259-268

[134] Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone, 2011, 49:50-55

[135] Plotkin LI et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J. Clin. Investig., 1999, 104:1363-1374

[136] Marolt D, Cozin M, Vunjak-Novakovic G, Cremers S, Landesberg R. Effects of pamidronate on human alveolar osteoblasts in vitro. J. Oral. Maxillofac. Surg., 2012, 70:1081-1092

[137] Shimizu E, Tamasi J, Partridge NC. Alendronate affects osteoblast functions by crosstalk through EphrinB1-EphB. J. Dent. Res., 2012, 91:268-274

[138] Idris AI, Rojas J, Greig IR, Van’t Hof RJ, Ralston SH. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif. Tissue Int., 2008, 82:191-201

[139] Gandolfi MG et al. Osteoblast behaviour in the presence of bisphosphonates: ultrastructural and biochemical in vitro studies. Clin. Exp. Rheumatol., 1999, 17:327-333

[140] Giannasi C et al. Nitrogen containing bisphosphonates impair the release of bone homeostasis mediators and matrix production by human primary pre-osteoblasts. Int. J. Med. Sci., 2019, 16:23-32

[141] Huja SS, Fernandez SA, Phillips C, Li Y. Zoledronic acid decreases bone formation without causing osteocyte death in mice. Arch. Oral Biol., 2009, 54:851-856

[142] Alemi AS et al. Glucocorticoids cause mandibular bone fragility and suppress osteocyte perilacunar-canalicular remodeling. Bone Rep., 2018, 9:145-153

[143] George EL, Lin YL, Saunders MM. Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. Bone Rep., 2018, 8:104-109

[144] Tamaoka J et al. Osteonecrosis of the jaws caused by bisphosphonate treatment and oxidative stress in mice. Exp. Ther. Med, 2019, 17:1440-144

[145] Burr DB, Allen MR. Mandibular necrosis in beagle dogs treated with bisphosphonates. Orthod. Craniofac. Res., 2009, 12:221-228

[146] Dole NS et al. Osteocyte-intrinsic TGF-beta signaling regulates bone quality through perilacunar/canalicular remodeling. Cell. Rep., 2017, 21:2585-2596

[147] Fowler TW et al. Glucocorticoid suppression of osteocyte perilacunar remodeling is associated with subchondral bone degeneration in osteonecrosis. Sci. Rep., 2017, 7

[148] Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Investig., 1998, 102:274-282

[149] Kuroshima S et al. Transplantation of noncultured stromal vascular fraction cells of adipose tissue ameliorates osteonecrosis of the jaw-like lesions in mice. J. Bone Min. Res, 2018, 33:154-166

[150] Kaibuchi N et al. Allogeneic multipotent mesenchymal stromal cell sheet transplantation promotes healthy healing of wounds caused by zoledronate and dexamethasone in canine mandibular bones. Regen. Ther., 2019, 10:77-83

[151] Lombard T, Neirinckx V, Rogister B, Gilon Y, Wislet S. Medication-related osteonecrosis of the jaw: new insights into molecular mechanisms and cellular therapeutic approaches. Stem Cells Int., 2016, 2016:8768162

[152] Lee, D. W. et al. The effect of polydeoxyribonucleotide extracted from salmon sperm on the restoration of bisphosphonate-related osteonecrosis of the jaw. Mar. Drugs. 17, pii: E51 (2019).

[153] Kim S, Kim J, Choi J, Jeong W, Kwon S. Polydeoxyribonucleotide improves peripheral tissue oxygenation and accelerates angiogenesis in diabetic foot ulcers. Arch. Plast. Surg., 2017, 44:482-489

[154] Howie RN et al. Removal of pamidronate from bone in rats using systemic and local chelation. Arch. Oral Biol., 2015, 60:1699-1707

[155] Elsayed R et al. Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function. Bone, 2018, 110:141-149

[156] Hokugo A et al. Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice. Bone, 2019, 123:115-128

[157] Kuroshima S, Entezami P, McCauley LK, Yamashita J. Early effects of parathyroid hormone on bisphosphonate/steroid-associated compromised osseous wound healing. Osteoporos. Int., 2014, 25:1141-1150

[158] Kuroshima S, Kovacic BL, Kozloff KM, McCauley LK, Yamashita J. Intra-oral PTH administration promotes tooth extraction socket healing. J. Dent. Res., 2013, 92:553-559

[159] Kwon, Y. D. & Kim, D. Y. Role of teriparatide in medication-related osteonecrosis of the jaws (MRONJ). Dent. J. 4, pii: E41 (2016).

[160] Zushi Y et al. Treatment with teriparatide for advanced bisphosphonate-related osteonecrosis of the jaw around dental implants: a case report. Int J. Implant Dent., 2017, 3

[161] Grey A. Teriparatide for bone loss in the jaw. N. Engl. J. Med., 2010, 363:2458-2459

[162] Gupta OP, Shaw JH. Periodontal disease in the rice rat. I. Anatomic and histopathologic findings. Oral Surg. Oral Med Oral Pathol., 1956, 9:592-603

[163] Aguirre JI et al. Breeding, husbandry, veterinary care, and hematology of marsh rice rats (Oryzomys palustris), a small animal model for periodontitis. J. Am. Assoc. Lab Anim. Sci., 2015, 54:51-58

[164] Leonard EP. Periodontitis. Animal model: periodontitis in the rice rat (Oryzomys palustris). Am. J. Pathol., 1979, 96:643-646

[165] Messer JG et al. Prevalence of food impaction-induced periodontitis in conventionally housed marsh rice Rats (Oryzomys palustris). Comp. Med, 2017, 67:43-50

[166] Aguirre JI et al. Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J. Bone Min. Res., 2012, 27:2130-2143

[167] Aghaloo TL et al. Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J. Bone Min. Res., 2011, 26:1871-1882

[168] Kang B et al. Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J. Bone Min. Res., 2013, 28:1631-1640

[169] Voss PJ et al. Zoledronate induces osteonecrosis of the jaw in sheep. J. Cranio-Maxillo-Facial Surg. Off. Publ. Eur. Assoc. Cranio-Maxillo-Facial Surg., 2015, 43:1133-1138

[170] Allen MR. Animal models of osteonecrosis of the jaw. J. Musculoskelet. Neuronal Interact., 2007, 7:358-360

[171] Larson MJ, Oakes AB, Epperson E, Chew DJ. Medication-related osteonecrosis of the jaw after long-term bisphosphonate treatment in a cat. J. Vet. Intern. Med., 2019, 33:862-867

[172] Allen MR, Chu TM, Ruggiero SL. Absence of exposed bone following dental extraction in beagle dogs treated with 9 months of high-dose zoledronic acid combined with dexamethasone. J. Oral. Maxillofac. Surg., 2013, 71:1017-1026